Lupin Manufacturing Solutions Expands Dabhasa Facility to Bolster Peptide Capabilities
Mumbai, March 19, 2026: Lupin Manufacturing Solutions (LMS), a subsidiary of Lupin Limited, announced a strategic expansion of its Dabhasa manufacturing facility in India. The expansion aims to scale its peptide building-blocks platform and Contract Development and Manufacturing Organization (CRDMO) capabilities.The upgraded facility includes a new block designed to enhance existing CRDMO capabilities, supported by dedicated peptide manufacturing capacity across two specialized units. These enhancements will enable advanced development and flexible manufacturing, catering to the growing global demand for complex pharmaceutical solutions.
“As pharmaceutical innovation increasingly shifts toward complex modalities, building deep capabilities and execution excellence has become critical,” stated Dr. Abdelaziz Toumi, Chief Executive Officer of Lupin Manufacturing Solutions. "This expansion underscores our commitment to building advanced, scalable capabilities that support complex development programs and reinforce our role in the global peptide ecosystem.”
The expansion reinforces LMS's capability to supply high-quality peptide building blocks, including protected amino acids, amidst increasing complexity in global drug development, particularly in areas like peptides and biologic ADCs.
About Lupin Manufacturing Solutions
Lupin Manufacturing Solutions Limited is a wholly-owned subsidiary of Lupin Limited and a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and a global CDMO. The company offers integrated solutions across drug substances, complex chemistry, drug product, and advanced modalities, including ADCs and peptides, supported by a team of over 250 scientists.
About Lupin
Lupin Limited is a global pharmaceutical company based in Mumbai, India, distributing products in over 100 markets. The company focuses on branded and generic formulations, complex generics, biotechnology products, and APIs, with a strong presence in India and the U.S. across multiple therapeutic areas. Lupin operates 15 manufacturing sites and 7 research centers globally, employing over 24,000 professionals.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.